Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral announces second quarter 2013 results


TORONTO, Aug. 13, 2013 /CNW/ - Spectral Diagnostics Inc., (TSX:SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with severe sepsis and septic shock, today announced its unaudited financial results for the second quarter ended June 30, 2013.

Second Quarter Highlights:

  • Enrolled patients into the Company's Phase III EUPHRATES trial at an accelerated rate compared to the prior year. Directed by the Company's Endotoxin Activity Assay (EAA™), which is the only FDA-cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is targeted to enroll 306 evaluable patients. Contingent on maintaining current enrollment rates and timely site start ups, the trial should be fully enrolled in the second half of 2014. As of August 12, 2013, 159 patients have been randomized into Spectral's EUPHRATES trial.

  • Announced the appointment of Dr. Gualtiero Guadagni as the Company's Vice President, Sales and Marketing. Dr. Guadagni will primarily be responsible for the development and expansion of commercial activities and market preparation plans for Toraymyxin and Spectral's Endotoxin Activity Assay (EAA™) in Canada, the United States and Europe.

  • Closed a private placement for gross proceeds of $5.6 million.

  • Concluded the reporting period with approximately $10.6 million in cash, cash equivalents and short-term investments.

  • Subsequent to quarter end, disclosed that the trial's composite 28-day mortality rate was approximately 33 per cent for randomized patients. The composite mortality rate continues to suggest that the Company is enrolling patients who are most likely to benefit from Spectral's treatment.

"We made excellent progress with the trial's patient enrollment in the second quarter, which moves us closer to the study's planned, second interim analysis," stated Dr. Paul Walker, President and CEO of Spectral. "We are optimistic that the results from the second interim analysis should support the successful completion of the trial."

At the second interim analysis, the Data and Safety Monitoring Board will advise the Company on the trial's safety, efficacy or futility, with stopping rules in place for efficacy and futility. A sample size recalculation will be done if necessary. Management intends to disclose the results of the interim analysis after 184 patients have been randomized and followed for 28 days, and the data from the analysis has been thoroughly reviewed.

Spectral remains on track to disclose information from the second interim analysis in late 2013 or early 2014.

Financial Review

Revenue for the three months ended June 30, 2013 was $572,000 compared to $599,000 for the same period in the preceding year. For the six months ended June 30, 2013 revenue was $1,280,000 compared to $1,275,000 for the same period in 2012. It is anticipated that revenue in 2013 will remain consistent with levels achieved in 2012.

Total expenses for the three months ended June 30, 2013 were $3,642,000 compared to $2,798,000 in the second quarter of 2012. For the six months ended June 30, 2013, total expenses were $6,449,000 compared to $5,774,000 for the same period in 2012. The increase of $675,000 for the six months ended June 30, 2013 is primarily attributable to higher EUPHRATES trial costs ($1,261,000) due to the accelerated patient enrollment rate, offset by a $475,000 reduction in management service fees.

The Company continues to maintain a low cost operating structure for its base business and expects no material increase in non clinical operating costs in 2013.

The Company concluded the second quarter of 2013 with cash, cash equivalents and short-term investment of $10,600,000 compared to $10,562,000 as at December 31, 2012.

About Spectral Diagnostics

Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment of severe sepsis with septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis. Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis.

Toraymyxin has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 100,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for Toraymyxin, and in November 2010, signed an exclusive distribution agreement for this product in Canada. More than 350,000 patients are diagnosed with severe sepsis and septic shock in North America each year, representing a greater than $1 billion market opportunity for Spectral. Spectral is listed on the Toronto Stock Exchange under the symbol SDI, and on the OTCQX under the symbol DIAGF. For more information please visit

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities, the ability to manufacture products and supply the market, as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

Spectral Diagnostics Inc.
Condensed Interim Statement of Financial Position
(in thousands of Canadian dollars)
    June 30
  December 31
    $   $
    Unaudited   Audited
Current assets        
Cash and cash equivalents   5,459   5,425
Short-term investment   5,189   5,137
Trade and other receivables   563   590
Inventories   418   277
Prepayments   311   226
    11,940   11,655
Non-current assets        
Property, plant and equipment   631   497
Intangible assets   422   434
    1,053   931
Total assets   12,993   12,586
Current liabilities        
Trade and other payables   1,925   1,913
Deferred revenue   50   99
Total liabilities   1,975   2,012
Share capital   32,556   27,101
Contributed surplus   3,864   3,864
Other equity reserves   8,366   8,260
Deficit   (33,768)   (28,651)
Total equity   11,018   10,574
Total liabilities and equity   12,993   12,586

Spectral Diagnostics Inc.
Condensed Interim Statement of Loss and Comprehensive Loss
For the six months ended June, 2013 and 2012
(in thousands of Canadian dollars, except for share and per share data)
    Three months ended    Six months ended
      June 30     June 30
    2013 2012   2013 2012
    $ $   $ $
Revenue   572 599   1,280 1,275
Other income   14 30   19 66
Changes in inventories of finished goods and            
  work- in-process   38 52   121 151
Raw materials and consumables used   170 103   281 202
Employee benefits   714 641   1,454 1,406
Consulting and professional fees   1,874 1,056   3,178 2,246
Management services   175 375   275 750
Regulatory and investor relations   58 99   106 222
Travel and entertainment   451 313   670 459
Depreciation and amortization   59 55   114 106
Foreign exchange (gain)loss   (9) (7)   - 4
Other expenses   112 111   250 228
    3,642 2,798   6,449 5,774
Operating loss   (3,056) (2,169)   (5,150) (4,433)
Finance  income   16 18   33 34
Loss and comprehensive loss for the period   (3,040) (2,151)   (5,117) (4,399)
Basic and diluted loss per common share   (0.02) (0.02)   (0.04) (0.04)
Weighted average number of common shares            
  outstanding   132,139,805 113,883,394   123,062,031 113,883,394

Spectral Diagnostics Inc.
Condensed Interim Statement of Changes in Equity
(in thousands of Canadian dollars, except number of shares)
         Issued capital Contributed
Warrants   Deficit Total  equity
    Number $ $ $ $   $ $
Balance, January 1, 2012    113,883,394   27,101 3,864 2,939 5,143   (20,108) 18,939
Loss and comprehensive loss for                    
  the period   -   - - - -   (4,399) (4,399)
Share-based compensation   -   - - 123 -   - 123
Balance, June 30, 2012   113,883,394   27,101 3,864 3,062 5,143   (24,507) 14,663
Balance, January 1, 2013    113,883,394   27,101 3,864 3,117 5,143   (28,651) 10,574
Loss and comprehensive loss for                    
  the period   -   - - - -   (5,117) (5,117)
Private placement   18,666,667   5,455 - - -   - 5,455
Share-based compensation   -   - - 106 -   - 106
Balance, June 30, 2013   132,550,061   32,556 3,864 3,223 5,143   (33,768) 11,018

Spectral Diagnostics Inc.
Condensed Interim Statement of Cash Flows
For the six months ended June  30, 2013 and 2012
    Six months ended
    June 30   June 30
    2013   2012
    $   $
Cash flow provided by (used in)        
Operating activities        
Loss and comprehensive loss for the period   (5,117)   (4,399)
Adjustments for:        
  Depreciation on property, plant, and equipment   102   94
  Amortization of intangible assets   12   12
  Share-based compensation   106   123
Changes in items of working capital :        
  Trade and other  receivables   27   (125)
  Inventories   (141)   50
  Prepayments   (85)   133
  Trade and other payables   12   35
  Deferred revenue   (49)   (11)
Net cash used in operating activities   (5,133)   (4,088)
Investing activities        
Property, plant and equipment expenditures   (236)   (140)
Redemption of short-term investment   5,137   5,086
Purchase of short-term investment   (5,189)   (5,102)
Net cash used in investing activities   (288)   (156)
Financing activities        
Private placement   5,455   -
Net cash provided by financing activities   5,455   -
Increase(decrease) in cash and cash equivalents   34   (4,244)
Cash and cash equivalents, beginning of period   5,425   13,470
Cash and cash equivalents, end of period   5,459   9,226



SOURCE: Spectral Diagnostics Inc.

Anthony Businskas
Executive Vice President and CFO
416-626-3233 ext. 2200

Adam Peeler
Investor Relations
TMX Equicom
416-815-0700 ext. 225

Copyright CNW Group 2013